Radium of radium Curie used the residues after extraction of uranium from pitchblende. The uranium had been extracted by dissolution in sulfuric acid leaving radium sulfate, which is similar to barium sulfate but even less soluble in the residues. The residues also contained rather substantial amounts of barium sulfate which thus acted as a carrier for the radium sulfate. The first steps of the radium extraction process involved boiling with sodium hydroxide followed by hydrochloric acid treatment to remove as much as possible of other compounds. The remaining residue was then treated with sodium carbonate to convert the barium sulfate into
Radium chloride radon gas which in turn was used as a cancer treatment. Radium-223 dichloride (USP, radium chloride Ra 223), tradename Xofigo (formerly Alpharadin), is an alpha-emitting radiopharmaceutical. Bayer received FDA approval for this drug to treat prostate cancer osteoblastic bone metastases in May 2013. Radium chloride Ra 223 is one of the most potent drugs known. One dose (50 kBq/kg) in an adult is about 60 nanograms; this amount is 1/1000 the weight of an eyelash (75 micrograms). Radium chloride Radium chloride (RaCl) is a chemical compound of radium and chlorine, and the first radium compound isolated in a pure state.